Clinical trial
Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and…
NCT00193362 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193362 |
|---|---|
| Title | Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer |
| Official title | Phase III Randomized Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine as First-Line Chemotherapy for Stage IIIB and IV Non-Small Cell Lung Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Eli Lilly and Company Industry GlaxoSmithKline |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Paclitaxel, Carboplatin, Gemcitabine, Vinorelbine |
| Enrollment | 200 |
| Start date | Jun 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Sep 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Jul 28, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: